Skip to main content
TrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor about whether a trial is right for you.

Diabetic Macular Edema Clinical Trials

10 recruiting trials for Diabetic Macular Edema. Eligibility criteria explained in plain English.

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.
10
Total Trials
10
Recruiting Now
1
Phase 3 Trials
10
Sponsors

Recruiting Trials

RECRUITINGNCT06439576

Real World Evidence in China: Faricimab Use in Diabetic Macular Edema, Retinal Vein Occlusion, and Neovascular...

The Farseeing Study will explore long-term effectiveness, safety, and treatment patterns among patients being treated with faricimab in real-world, routine clinical practice in...

Sponsor: Hoffmann-La RocheEnrolling: 100020 locations
RECRUITINGPhase 2 / Phase 3NCT06595355

Efficacy and Safety of Intravitreal Injection of Bevacizumab with and Without Oral Curcumin

The purpose of this study is to evaluate the effectiveness of adding curcumin oral treatment to bevacizumab intravitreal injection in patients with central macular edema. A blind...

Sponsor: Isfahan University of Medical SciencesEnrolling: 521 location
RECRUITINGPhase 3NCT06305416

A Efficacy and Safety Study of Ranibizumab 10mg/ml Injection (Incepta) in Patients With Diabetic Macular Edema

Macular edema in diabetes, defined as retinal thickening within two disc diameters of the center of the macula, results from retinal microvascular changes that compromise the...

Sponsor: Incepta Pharmaceuticals LtdEnrolling: 701 location
RECRUITINGNCT06610747

Home- vs Hospital-based Care of Anti-VEGF Treatment for Diabetic Macular Edema: Non-inferiority RCT

Diabetic macular edema (DME) is a common cause of central visual loss in diabetic patients and a global public health burden around the world. Most patients with DME and vision...

Sponsor: Zhongshan Ophthalmic Center, Sun Yat-sen UniversityEnrolling: 3083 locations
RECRUITINGNCT06549023

Single Session vs Multiple-Session Panretinal Photocoagulation for Treatment of Proliferative Diabetic Retinopathy

Proliferative diabetic retinopathy (PDR) is the leading cause for blindness in working-age adults. The current gold standard treatment for PDR is panretinal photocoagulation...

Sponsor: Vastra Gotaland RegionEnrolling: 401 location
RECRUITINGNCT04699864

Evaluation of NeoRetina Artificial Intelligence Algorithm for the Screening of Diabetic Retinopathy at the CHUM

This prospective study aims to validate if NeoRetina, an artificial intelligence algorithm developped by DIAGNOS Inc. and trained to automatically detect the presence of diabetic...

Sponsor: Centre hospitalier de l'Université de Montréal (CHUM)Enrolling: 6301 location
RECRUITINGPhase 2NCT03161652

Effect of Levosulpiride on Retinal Alterations in Patients With Diabetic Retinopathy and Diabetic Macular Edema

This is a randomized, double-blind, placebo-controlled trial to evaluate the safety and efficacy of levosulpiride to improve retinal alterations due to diabetic macular edema and...

Sponsor: Carmen ClappEnrolling: 1202 locations
RECRUITINGNCT02669953

Aflibercept in Recurrent or Persistent CNV

Age-related macular degeneration (AMD) and diabetic retinopathy are among the most common disorders causing visual disability in elderly people. AMD leads to dysfunction and loss...

Sponsor: Medical University of ViennaEnrolling: 801 location
RECRUITINGPhase 1NCT06701721

A Study Intravitreal THN391 in Diabetic Macular Oedema Secondary to Non-Proliferative Diabetic Retinopathy.

THN391-OPT-101 is a study assessing safety and preliminary efficacy of THN391 in patients with diabetic macular edema (DME) given as monotherapy.

Sponsor: Therini Bio Pty LtdEnrolling: 212 locations
RECRUITINGPhase 1NCT04187443

MS-553 in Diabetic Retinopathy Patients With Central Involved Macular Edema

This is an open label dose-escalation study to evaluate the safety and treatment benefits of MS-553 in treatment-naive diabetic retinopathy patients with central involved macular...

Sponsor: Shenzhen MingSight Relin Pharmaceuticals Co., Ltd.Enrolling: 453 locations